Antibodies: Timeline of key events

Mouseover the event title for a more detailed description of the event (if available). To search for particular terms in the description of the event enter the term in the box below 'Event' on the table and press 'enter'. Alternatively use the dropdown lists to filter by Person, Place or Science. Click here to clear the filter.

Treatment was given to Leopold Fotso, a 33 year old man at King's College London using natalizumab, a drug licensed for multiple sclerosis. The trial is being led by Oliver Howe. 2017-11-03T00:00:00+0000Developed by Biogen, the drug, aducanumab, targets a protein called amyloid that forms abnormal deposits in the brains of people with Alzheimer's. The company originally discontinued work on the drug in March 2019 after disappointing trial results. 2019-10-22T00:00:00+0000
Date Event People Places Sciences
3 Nov 2017First patient treated in first clinical trial using monoclonal antibody drug to treat schizophreniaHoweKing's College LondonMonoclonal antibodies
22 Oct 2019Monoclonal drug originally dismissed for treating Alzheimers got new green light from FDA for testing for the disease BiogenMonoclonal antibodies

3 Nov 2017

First patient treated in first clinical trial using monoclonal antibody drug to treat schizophrenia

22 Oct 2019

Monoclonal drug originally dismissed for treating Alzheimers got new green light from FDA for testing for the disease